
Claims

1. A compound of Formula (I)



(I)

and/or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, wherein:

R^1 is H or LA;

R^2 is Hal, O(LA), N(LA)(LA)', CONH(LA), Ar, $CONH_2$ or A;

$R^{3'}$, $R^{3''}$ independently are H, LA or Hal,

Ar is a mono- or bicyclic aromatic homo- or heterocycle having 0, 1, 2, 3 or 4 N, O and/or S atoms and 5, 6, 7, 8, 9, or 10 skeleton atoms, which may be unsubstituted or, independently of one another, mono-, di- or trisubstituted by Hal, A, Ar1, OH, SH, OA, O(Ar1), NH_2, NHA, NH(Ar1), NA_2, NO_2, CN, OCN, SCN, COOH, COOA, $CONH_2$, CONHA, CONH(Ar1), $CONA_2$, NHCOA, NHCO(Ar1), NHCONHA, NHCONH(Ar1), $NHCONH_2$, $NHSO_2A$, $NHSO_2(Ar1)$, COA, CO(Ar1), SO_2NH_2, SO_2A, $SO_2(Ar1)$ and/or SO_2Hal, and in which a ring N-atom may be substituted by an O-atom to form an N-oxide group, and in which in the case of a bicyclic aromatic cycle on of the two rings may be partly saturated,

Ar1 is a monocyclic aromatic homo- or heterocycle having 0, 1, 2 or 3 N, O and/or S atoms and 5 or 6 skeleton atoms, which may be unsubstituted or, independently of one another, mono-, di- or trisubstituted by Hal, LA, OH, SH, O(LA), NH_2, NH(LA), $N(LA)_2$, NO_2, CN, OCN, SCN, COOH, COO(LA), $CONH_2$, CONH(LA), $CON(LA)_2$, NHCO(LA), CHO, CO(LA), SO_2NH_2, $SO_2(LA)$ and/or SO_2Hal,


A is unbranched or branched linear or cyclic alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 C atoms, in which one or two CH_2 groups may be replaced by an O or S

atom and/or by an –NH-, -CO-, -NHCOO-, -NHCONH-. -N(LA)-, -CONH-, -NHCO- or –CH=CH– group, and in which 1-3 H atoms may be replaced by Hal, and in which one or two CH_3 groups may be replaced by OH, SH, NH_2, NH(LA), $N(LA)_2$, NHCOOH, $NHCONH_2$ or CN,

LA is unbranched or branched, linear alkyl having 1, 2, 3 or 4 C atoms, wherein 1, 2 or 3 H atoms may be replaced by Hal, e.g. methyl, ethyl, trifluoromethyl, difluoromethyl, 1,1,1-trifluoroethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, and

Hal is F, Cl or Br.

2. The compound according to Claim 1, which is defined by Formula (II),



(II)

and/or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios,

wherein:


R^4, R^5, R^6, R^7, R^8, independently are H, Hal, LA, OH, SH, O(LA), NH_2, NH(LA), $N(LA)_2$, NO_2, CN, OCN, SCN, COOH, COO(LA), $CONH_2$, CONH(LA), $CON(LA)_2$, NHCO(LA), NHCONH(LA), $NHCONH_2$, $NHSO_2(LA)$, CO(LA), SO_2NH_2, $SO_2(LA)$ or SO_2Hal,

R^5, R^6 together with the phenyl group they are attached to, may form a 9 or 10 membered bicyclic ring system, in which 1 or 2 of the non-phenyl carbon atoms may be independently replaced by NH, O or S, in which the cycle formed by R^5 and R^6 may be unsubstituted or mono- or disubstituted by Hal or LA,


One of R^5, R^6, R^7

may be Ar1, O(Ar1), NH(Ar1), CONH(Ar1), NHCO(Ar1), NHCONH(Ar1), $NHSO_2(Ar1)$, CO(Ar1) or $SO_2(Ar1)$,
while the other two of R^5, R^6, R^7 are not Ar1, O(Ar1), NH(Ar1), CONH(Ar1), NHCO(Ar1), NHCONH(Ar1), $NHSO_2(Ar1)$, CO(Ar1) or $SO_2(Ar1)$,
and the remaining substituents have the meanings indicated for Formula (I).

3. The compound according to Claims 1 or 2, which is defined by Formulae (I') or (II'),



(I')



(II')

and/or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, wherein all substituents have the meanings indicated for Formulae (I) or (II).

4. The compound according to Claims 2 or 3, which conforms to Formulae (II) or (II'), or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, in which the residues not designated in greater detail have the meaning indicated for Formula (II), but in which

in Subformula 1

R^4, R^5, R^6, R^7, R^8	independently are H, F, Cl, Br, OH, LA, O(LA), CN, $C(Hal)_3$, $OC(Hal)_3$,

in Subformula 2

R^1, R^2	are H,

in Subformula 3

$R^{3'}$, $R^{3''}$	independently are H, OH or F,

in Subformula 4

R^4, R^8 independently are H, F or Cl,

in Subformula 5

R^5, R^7 independently are H, F, Cl, Br, CN, methoxy or CF_3,

in Subformula 6

R^5, R^6 together with the phenyl group they are attached to, form benzo-1,2-dioxolyl, of which the carbon atom bridging the two oxygen atoms may be unsubstituted, or mono- or disubstituted by F or methyl,

in Subformula 7

R^6 is H, F, Cl or CF_3,

in Subformula 8

R^5, R^6 independently are H, F, Cl, Br, methyl, CHF_2 or CF_3,

in Subformula 9

R^1, R^2, $R^{3'}$, $R^{3''}$, R^4, R^7, R^8 are H,

in Subformula 10

R^1, R^2, $R^{3'}$, $R^{3''}$, R^4, R^7, R^8 are H,

R^5, R^6 are independently H, F, Cl, Br, methyl, CHF_2 or CF_3,

in Subformula 11

R^1, R^2, $R^{3'}$, $R^{3''}$, R^4, R^8 are H,

R^5 is Br, methyl, CHF_2 or CF_3,

R^6 is F, Cl or CF_3,

R^7 is H or F,

in Subformula 12

R^1, R^2, R^4, R^8 are H,

$R^{3'}$ is F, or methyl,

$R^{3"}$	is H,
R^5	is Br, methyl, CHF_2 or CF_3,
R^6	is F, Cl or CF_3,
R^7	is H or F,

5. The compound according to Claim 1, wherein the compound is selected from the group consisting of:
4-[(S)-2-Azetidin-1-yl-1-(3-fluorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(3-chlorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(4-fluorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(3,4-difluorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(4-chloro-3-trifluoromethylphenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(3-fluoro-5-trifluoromethylphenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(3-chloro-4-fluorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(4-bromophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(4-trifluoromethylphenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(4-chlorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(3-cyanophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(3-methoxyphenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(3-bromophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(2-fluoro-4-chlorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(2,4-difluorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(2,6-difluorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(3-chloro-4-trifluoromethylphenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(2,4,5-trifluorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(2,3,4-trifluorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(1-benzo[1,3]dioxol)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-phenyl-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-(3-Fluoro-azetidin-1-yl)-1-(3-chlorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(4-cyano-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(2-chloro-4-fluoro-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(2-chloro-5-fluoro-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(2,5-di-fluoro-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(3-chloro-4-trifluoromethoxy-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(4-chloro-3-fluoro-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(4-trifluoromethoxy-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(4-fluoro-3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-1-(4-Chloro-phenyl)-2-(3,3-difluoro-azetidin-1-yl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-1-(3,4-Difluoro-phenyl)-2-(3-hydroxy-azetidin-1-yl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(4-isopropylphenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(4-carbamoylphenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(4-isopropoxyphenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(3,4,5-trifluorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(3,5-difluoro-4-methoxyphenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(3-cyano-4-fluorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(3,4-difluoro-5-methoxyphenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(3-fluoro-4,5-dichlorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(4-fluoro-3-methyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(4-fluoro-3-methoxy-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(3-difluoromethyl-4-fluoro-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(4-fluoro-3-trifluoromethyl-phenyl)-ethylamino]-6-fluoro-quinazoline-8-carboxylic acid amide;
4-[(S)-1-(4-Fluoro-3-trifluoromethyl-phenyl)-2-(3-methyl-azetidin-1-yl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(4-fluoro-3-trifluoromethyl-phenyl)-ethylamino]-6-methoxy-quinazoline-8-carboxylic acid amide;
4-[(S)-1-(4-Fluoro-3-trifluoromethyl-phenyl)-2-(2-methyl-azetidin-1-yl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-(3-Fluoro-azetidin-1-yl)-1-(4-fluoro-3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(3-cyano-4-fluoro-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(4-chloro-3-fluoro-phenyl)-ethylamino]-6-fluoro-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(4-benzoylamino-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-(3-Fluoro-azetidin-1-yl)-1-(4-chloro-3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
and/or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios.

6. A pharmaceutical composition comprising a compound according to any of claims 1 to 5, and/or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, as active ingredient, together with a pharmaceutically acceptable carrier.

7. A compound of any of claims 1 to 5, and/or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, for use as a medicament.

8. A compound of any of claims 1 to 5, and/or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, for treating hyperproliferative diseases.

9. The compound of claim 8, and/or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, wherein the disease is selected from the group consisting of cancer, inflammation, pancreatitis or kidney disease, pain, benign hyperplasia of the skin, restenosis, prostate, diseases related to vasculogenesis or angiogenesis, tumor angiogenesis, skin diseases selected from psoriasis, eczema, and sclerodema, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma and Kaposi's sarcoma.

10. Use of a compound of any of claims 1 to 5, or and/or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of hyperproliferative diseases.

11. Use according to claim 10 wherein the disease is selected from the group consisting of cancer, inflammation, pancreatitis or kidney disease, pain, benign hyperplasia of the skin, restenosis, prostate, diseases related to vasculogenesis or angiogenesis, tumor angiogenesis, skin diseases selected from psoriasis, eczema, and sclerodema, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma and Kaposi's sarcoma.

12. A method for treating hyperproliferative diseases, comprising administering to a subject a compound of any of claims 1 to 5, and/or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios.

13. The method of claim 12, wherein the disease is selected from the group consisting of cancer, inflammation, pancreatitis or kidney disease, pain, benign hyperplasia of the skin, restenosis, prostate, diseases related to vasculogenesis or angiogenesis, tumor angiogenesis, skin diseases selected from psoriasis, eczema, and sclerodema, diabetes, diabetic retinopathy, retinopathy of prematurity, age-related macular degeneration, hemangioma, glioma, melanoma and Kaposi's sarcoma.


14. Set (kit) consisting of separate packs of

a) an effective amount of a compound according to any of Claims 1 to 5 and/or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, and

b) an effective amount of a further medicament active ingredient.


15. Process for the manufacture of compounds of Formula (I), wherein LG is a leaving group, and the remaining substituents have the meaning as defined for Formula (I) in Claim 1,

wherein a compound of Formula (V)




(V),

is reacted with a compound of Formula (IV)



(IV),

to yield a carboxylic ester compound of Formula (III),




(III),

which is then converted to a carboxamide compound of Formula (I).

Claims

1. A compound of Formula (II')



(II')

and/or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, wherein:

R^1, R^2 are H,

$R^{3'}$, $R^{3''}$ independently are H, LA or Hal,

R^4, R^5, R^6, R^7, R^8, independently are H, Hal, LA, OH, SH, O(LA), NH_2, NH(LA), $N(LA)_2$, NO_2, CN, OCN, SCN, COOH, COO(LA), $CONH_2$, CONH(LA), $CON(LA)_2$, NHCO(LA), NHCONH(LA), $NHCONH_2$, $NHSO_2(LA)$, CO(LA), SO_2NH_2, $SO_2(LA)$ or SO_2Hal,

R^5, R^6 together with the phenyl group they are attached to, may form a 9 or 10 membered bicyclic ring system, in which 1 or 2 of the non-phenyl carbon atoms may be independently replaced by NH, O or S, in which the cycle formed by R^5 and R^6 may be unsubstituted or mono- or disubstituted by Hal or LA,

One of R^5, R^6, R^7

may be Ar1, O(Ar1), NH(Ar1), CONH(Ar1), NHCO(Ar1), NHCONH(Ar1), $NHSO_2(Ar1)$, CO(Ar1) or $SO_2(Ar1)$,

while the other two of R^5, R^6, R^7 are not Ar1, O(Ar1), NH(Ar1), CONH(Ar1), NHCO(Ar1), NHCONH(Ar1), $NHSO_2(Ar1)$, CO(Ar1) or $SO_2(Ar1)$,

Ar1 is a monocyclic aromatic homo- or heterocycle having 0, 1, 2 or 3 N, O and/or S atoms and 5 or 6 skeleton atoms, which may be unsubstituted or, independently of one another, mono-, di- or trisubstituted by Hal, LA, OH, SH, O(LA), NH_2,

NH(LA), N(LA)$_2$, NO_2, CN, OCN, SCN, COOH, COO(LA), $CONH_2$, CONH(LA), CON(LA)$_2$, NHCO(LA), CHO, CO(LA), SO_2NH_2, SO_2(LA) and/or SO_2Hal,

LA is unbranched or branched, linear alkyl having 1, 2, 3 or 4 C atoms, wherein 1, 2 or 3 H atoms may be replaced by Hal, and

Hal is F, Cl or Br.

2. The compound according to Claim 1, which conforms to Formula (II'), or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, in which the residues not designated in greater detail have the meaning indicated for Formula (II'), but in which

in Subformula 1

R^4, R^5, R^6, R^7, R^8 independently are H, F, Cl, Br, OH, LA, O(LA), CN, $C(Hal)_3$, $OC(Hal)_3$,

in Subformula 2

$R^{3'}$, $R^{3''}$ independently are H or F,

in Subformula 3

R^4, R^8 independently are H, F or Cl,

in Subformula 4

R^5, R^7 independently are H, F, Cl, Br, CN, methoxy or CF_3,

in Subformula 5

R^5, R^6 together with the phenyl group they are attached to, form benzo-1,2-dioxolyl, of which the carbon atom bridging the two oxygen atoms may be unsubstituted, or mono- or disubstituted by F or methyl,

in Subformula 6

R^6 is H, F, Cl or CF_3,

in Subformula 7

R^5, R^6 independently are H, F, Cl, Br, methyl, CHF_2 or CF_3,

in Subformula 8

R^1, R^2, $R^{3'}$, $R^{3''}$, R^4, R^7, R^8 are H,

in Subformula 9

R^1, R^2, $R^{3'}$, $R^{3''}$, R^4, R^7, R^8 are H,

R^5, R^6 are independently H, F, Cl, Br, methyl, CHF_2 or CF_3,

in Subformula 10

R^1, R^2, $R^{3'}$, $R^{3''}$, R^4, R^8 are H,

R^5 is Br, methyl, CHF_2 or CF_3,

R^6 is F, Cl or CF_3,

R^7 is H or F,

in Subformula 11

R^1, R^2, R^4, R^8 are H,

$R^{3'}$ is F, or methyl,

$R^{3''}$ is H,

R^5 is Br, methyl, CHF_2 or CF_3,

R^6 is F, Cl or CF_3,

R^7 is H or F,

3. The compound according to Claim 1, wherein the compound is selected from the group consisting of:

4-[(S)-2-Azetidin-1-yl-1-(3-fluorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(3-chlorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(4-fluorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(3,4-difluorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(4-chloro-3-trifluoromethylphenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(3-fluoro-5-trifluoromethylphenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(3-chloro-4-fluorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(4-bromophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(4-trifluoromethylphenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(4-chlorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(3-cyanophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(3-methoxyphenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(3-bromophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(2-fluoro-4-chlorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(2,4-difluorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(2,6-difluorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(3-chloro-4-trifluoromethylphenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(2,4,5-trifluorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(2,3,4-trifluorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(1-benzo[1,3]dioxol)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-phenyl-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-(3-Fluoro-azetidin-1-yl)-1-(3-chlorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(4-cyano-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(2-chloro-4-fluoro-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(2-chloro-5-fluoro-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(2,5-di-fluoro-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(3-chloro-4-trifluoromethoxy-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(4-chloro-3-fluoro-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(4-trifluoromethoxy-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(4-fluoro-3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-1-(4-Chloro-phenyl)-2-(3,3-difluoro-azetidin-1-yl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(4-isopropylphenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(4-carbamoylphenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(4-isopropoxyphenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(3,4,5-trifluorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(3,5-difluoro-4-methoxyphenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(3-cyano-4-fluorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(3,4-difluoro-5-methoxyphenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(3-fluoro-4,5-dichlorophenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(4-fluoro-3-methyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;

4-[(S)-2-Azetidin-1-yl-1-(4-fluoro-3-methoxy-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(3-difluoromethyl-4-fluoro-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(4-fluoro-3-trifluoromethyl-phenyl)-ethylamino]-6-fluoro-quinazoline-8-carboxylic acid amide;
4-[(S)-1-(4-Fluoro-3-trifluoromethyl-phenyl)-2-(3-methyl-azetidin-1-yl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-1-(4-Fluoro-3-trifluoromethyl-phenyl)-2-(2-methyl-azetidin-1-yl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-(3-Fluoro-azetidin-1-yl)-1-(4-fluoro-3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(3-cyano-4-fluoro-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(4-chloro-3-fluoro-phenyl)-ethylamino]-6-fluoro-quinazoline-8-carboxylic acid amide;
4-[(S)-2-Azetidin-1-yl-1-(4-benzoylamino-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
4-[(S)-2-(3-Fluoro-azetidin-1-yl)-1-(4-chloro-3-trifluoromethyl-phenyl)-ethylamino]-quinazoline-8-carboxylic acid amide;
and/or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios.

4. A pharmaceutical composition comprising a compound according to any of claims 1 to 3, and/or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, as active ingredient, together with a pharmaceutically acceptable carrier.

5. A compound of any of claims 1 to 3, and/or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, for use as a medicament.

6. A compound of any of claims 1 to 3, and/or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, for treating hyperproliferative diseases.

7. The compound for use according to of claim 6, and/or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, wherein the hyperproliferative disease is cancer.

8. The compound for use according to of claim 7, and/or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, wherein the cancer is selected from a group consisting of brain, lung, colon, epidermoid, squamous cell, bladder, gastric, pancreatic, breast, head, neck, renal, kidney, liver, ovarian, prostate, colorectal, uterine, rectal, oesophageal, testicular, gynecological, or thyroid cancer, or melanoma, hematologic malignancies such as acute myelogenous leukemia, multiple myeloma, chronic myelogneous leukemia, myeloid cell leukemia, glioma, Kaposi's sarcoma.

9. Use of a compound of any of claims 1 to 3, or and/or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of hyperproliferative diseases.

10. Use according to claim 9 wherein the hyperproliferative disease is cancer.

11. Use according to claim 10 wherein the cancer is selected from a group consisting of brain, lung, colon, epidermoid, squamous cell, bladder, gastric, pancreatic, breast, head, neck, renal, kidney, liver, ovarian, prostate, colorectal, uterine, rectal, oesophageal, testicular, gynecological, or thyroid cancer, or melanoma, hematologic malignancies such as acute myelogenous leukemia, multiple myeloma, chronic myelogneous leukemia, myeloid cell leukemia, glioma, Kaposi's sarcoma.


12. Set (kit) consisting of separate packs of

a) an effective amount of a compound according to any of Claims 1 to 3 and/or its stereoisomers or tautomers, or pharmaceutically acceptable salts of each of the foregoing, including mixtures thereof in all ratios, and

b) an effective amount of a further medicament active ingredient.


13. Process for the manufacture of compounds of Formula (II'), wherein LG is a leaving group, and the remaining substituents have the meaning as defined for Formula (II') in Claim 1,

wherein a compound of Formula (V)




(V),

is reacted with a compound of Formula (IV)



(IV),

to yield a carboxylic ester compound of Formula (III),



(III),

which is then converted to a carboxamide compound of Formula (II').